English  |  正體中文  |  简体中文  |  总笔数 :2828323  
造访人次 :  32225332    在线人数 :  974
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"zhou caicun"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 1-8 / 8 (共1页)
1 
每页显示[10|25|50]项目

机构 日期 题名 作者
國立臺灣大學 2015 Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials Yang, James Chih-Hsin; Wu, Yi-Long; Schuler, Martin; Sebastian, Martin; Popat, Sanjay; Yamamoto, Nobuyuki; Zhou, Caicun; Hu, Cheng-Ping; O'Byrne, Kenneth; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Geater, Sarayut L.; Lee, Kye Young; Tsai, Chun-Ming; Gorbunova, Vera; Hirsh, Vera; Bennouna, Jaafar; Orlov, Sergey; Mok, Tony; Boyer, Michael; Su, Wu-Chou; Lee, Ki Hyeong; Kato, Terufumi; Massey, Dan; Shahidi, Mehdi; Zazulina, Victoria; Sequist, Lecia V.; 楊志新
國立臺灣大學 2015 Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis Lee, Chee Khoon; Wu, Yi-Long; Ding, Pei Ni; Lord, Sarah J.; Inoue, Akira; Zhou, Caicun; Mitsudomi, Tetsuya; Rosell, Rafael; Pavlakis, Nick; Links, Matthew; Gebski, Val; Gralla, Richard J.; Yang, James Chih-Hsin; 楊志新
國立臺灣大學 2015 Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 Yang, James C-H; Sequist, Lecia V.; Geater, Sarayut Lucien; Tsai, Chun-Ming; Mok, Tony Shu Kam; Schuler, Martin; Yamamoto, Nobuyuki; Yu, Chong-Jen; Ou, Sai-Hong I.; Zhou, Caicun; Massey, Daniel; Zazulina, Victoria; Wu, Yi-Long; 楊志新; 余忠仁
國立臺灣大學 2015 The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials. Lee, Chee; Davies, Lucy Claire; Wu, Yi-Long; Mitsudomi, Tetsuya; Inoue, Akira; Rosell, Rafael; Zhou, Caicun; Nakagawa, Kazuhiko; Throngprasert, Sumitra; Fukuoka, Masahiro; Gralla, Richard J.; Gebski, Val; Mok, Tony; Yang, James Chih-Hsin; 楊志新
國立臺灣大學 2013 Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial Wu, Yi-Long; Lee, Jin Soo; Thongprasert, Sumitra; Yu, Chong-Jen; Zhang, Li; Ladrera, Guia; Srimuninnimit, Vichien; Sriuranpong, Virote; Sandoval-Tan, Jennifer; Zhu, Yunzhong; Liao, Meilin; Zhou, Caicun; Pan, Hongming; Lee, Victor; Chen, Yuh-Min; Sun, Yan; Margono, Benjamin; Fuerte, Fatima; Chang, Gee-Chen; Seetalarom, Kasan; Wang, Jie; Cheng, Ashley; Syahruddin, Elisna; Qian, Xiaoping; Ho, James; Kurnianda, Johan; Liu, Hsingjin Eugene; Jin, Kate; Truman, Matt; Bara, Ilze; Mok, Tony; 余忠仁
國立成功大學 2012-05 Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin
國立臺灣大學 2012 A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II Mok, Tony; Wu, Yi Long; Thongprasert, Sumitra; Yu, Chong-Jen; Zhang, Li; Ladrera, Guia Elena; Srimuninnimit, Vichien; Sriuranpong, Virote; Sandoval-Tan, Jennifer; Zhu, Yunzhong; Liao, Meilin; Zhou, Caicun; Pan, Hongming; Lee, Victor; Chen, Yuh-Min; Sun, Yan; Margono, Benjamin; Jin, Kate; Truman, Matt; Lee, Jin Soo; 余忠仁
國立臺灣大學 2012 Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin; 楊志新

显示项目 1-8 / 8 (共1页)
1 
每页显示[10|25|50]项目